LexaGene Holdings Inc. (OTCMKTS:LXXGF – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 152,500 shares, a decrease of 9.0% from the December 31st total of 167,500 shares. Based on an average trading volume of 300,700 shares, the days-to-cover ratio is presently 0.5 days.
LexaGene Stock Performance
Shares of LexaGene stock opened at 0.20 on Monday. LexaGene has a 1 year low of 0.05 and a 1 year high of 0.32. The business has a 50-day moving average of 0.16 and a two-hundred day moving average of 0.13.
Get
LexaGene alerts:
About LexaGene
(Get Rating)
LexaGene Holdings Inc, a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets.
Featured Stories
- Get a free copy of the StockNews.com research report on LexaGene (LXXGF)
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- Capital One Stock: Will Subprime Borrowers Spoil the Rally?
Receive News & Ratings for LexaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LexaGene and related companies with MarketBeat.com's FREE daily email newsletter.
利盟基因控股有限公司(場外交易代碼:LXXGF-GET Rating)是空頭股數在1月份大幅下降的目標。截至1月15日,空頭股數共有15.25萬股,比12月31日的16.75萬股減少了9.0%。以300,700股的平均成交量計算,目前天數與回補比率為0.5天。
Lexagene股票表現
週一,Lexagene的股票開盤報0.20英鎊。Lexagene的一年低點為0.05,一年高位為0.32。該業務的50日移動均線切入位在0.16,200日移動均線切入位在0.13。
到達
Lexagene警報:
關於Lexagene
(獲取評級)
Lexagene控股公司是一家生物技術公司,從事病原體檢測系統的研究、開發和商業化。它提供MiQLab,這是一種自動病原體檢測系統,旨在改變獸醫診斷、人類臨床診斷、食品和水安全測試以及其他生命科學市場中的病原體檢測。
專題報道
- 免費獲取StockNews.com關於Lexagene的研究報告(LXXGF)
- EHealth股票從灰燼中崛起。是時候上車了嗎?
- Yext AI蒐索平臺能否推動2023年的增長?
- 木薯科學公司的股票以124美元的目標價被低估了?
- 星座品牌:消費者正在降低購買鐵路飲料的價格嗎?
- Capital One股票:次級借款人會破壞漲勢嗎?
接受Lexagene日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Lexagene和相關公司的最新新聞和分析師評級的每日簡要摘要。